PRODUCTS

  • Avance Clinical offers deep scientific expertise and extensive knowledge across a range of specialized therapeutic indications, consistently achieving global regulatory approvals.

  • Antibody drug conjugates (ADCs) are the emerging class of anti-cancer therapeutic drugs. ADCs combine an antibody capable of recognizing cancer cells and cytotoxic small-molecule drugs via cleavable or non-cleavable linkers, thereby transforming the 3-unit combination into a targeted therapeutic drug for cancer treatment. In recent years, ADCs have rapidly developed and there are not only more than 14 approved drugs on the market but also many investigational drugs undergoing clinical trials. Furthermore, ADCs have shown potential for treating various diseases beyond cancer, such as Autoimmune disorders, Infectious diseases, Inflammatory conditions and so on.  

  • ClinAI helps you centralize RFPs, budgets, and vendor data—so you can select the right partners, manage change orders, and keep your studies on track.

  • Take advantage of our end-to-end DMPK expertise for optimizing compounds from discovery through IND filing for small and large molecules

  • The MMPX-00002PSM is a passive MMIC (Monolithic Microwave Integrated Circuit) quadplexer designed to multiplex signals across four distinct frequency bands: DC–6 GHz, 8–10 GHz, 12–14 GHz, and 16–18 GHz.

WHITE PAPERS & CASE STUDIES

NEWS

ABOUT